Coherus’s Low List Price Adalimumab Stacking Up PBM And Pharmacy Partnerships

Analysts Still Confident In Humira’s Market Share Despite Increasing Competition

 
• By Chloe Kent

Coherus has made deals with numerous pharmacy benefit managers and pharmacies to bring its low list price Yusimry adalimumab biosimilar to patients, as analysts continue to back Humira originator AbbVie as market leader. 

Yusimry pen and packaging
Two PBMs have agreed to supply Yusimry through the Mark Cuban Cost Plus Drug Company • Source: Coherus Biosciences

More from Biosimilars

More from Products